Compound 1 Synthesis for High Yield and Enantiomeric Purity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for more efficient syntheses of Compound 1, a selective estrogen receptor alpha (ERα) modulator/degrader (SERM/SERD), to meet the demand for increased quantities required for clinical studies and potential commercial use in treating ER+ cancers such as breast cancer.
Innovation Solution
A series of processes involving transition metal catalysts, bases, and reducing agents are employed to synthesize Compound 1, including cross-coupling reactions, reductions, and enantiomeric enhancements using chiral acids to achieve high yields and enantiomeric excess.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional synthesis methods are used to produce Compound 1, then the basic synthesis can be achieved, but the yield and enantiomeric purity are insufficient for clinical study requirements
Solution Approach 1:
The patent employs parameter changes by systematically optimizing reaction conditions including temperature, solvent composition, base selection, and catalyst loading to achieve both high yield and high enantiomeric purity. The cross-coupling reaction parameters are specifically tuned to favor the formation of the desired enantiomer while maintaining high productivity.
Solution Approach 2:
The patent uses chiral auxiliaries and resolving agents as intermediaries to achieve high enantiomeric purity. These intermediaries temporarily associate with the racemic mixture or intermediates to enable separation of enantiomers, which are then removed to yield the pure desired enantiomer of Compound 1.
2Manufacturing precision
If synthesis conditions are optimized for high enantiomeric purity, then the enantiomeric excess improves, but the overall productivity and yield may decrease
Solution Approach 1:
The patent applies preliminary action by performing kinetic resolution or diastereomeric salt formation early in the synthesis pathway, before the final product formation. This allows the enantiomeric separation to occur at a stage where the material is more easily manipulated and where the resolution can be performed with higher efficiency, thereby maintaining overall yield.
Solution Approach 2:
The patent replaces mechanical separation methods with chemical resolution methods using chiral bases or acids. This substitution allows for more efficient enantiomeric separation that does not require multiple purification steps, thereby maintaining high productivity while achieving high enantiomeric excess.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The processes provide unexpectedly improved yields and enantiomeric purity of Compound 1, facilitating its production for preclinical and clinical studies and potential commercial use.
Implementation Method 1
the reaction of a compound of formula (I) with a compound of formula (II) in the presence of a base and a transition metal catalyst; wherein said X and X′ are suitable for cross-coupling of compound (I) with compound (II)
Implementation Method 2
the reduction of a compound of formula (III) in the presence of a reducing agent
Implementation Method 3
crystallizing the enantiomerically enriched salt
Data Source
AI summary
Useful processes of preparation and intermediates useful for the preparation of Compound 1, a selective estrogen receptor alpha (ERα) modulator/degrader (SERM/SERD), having utility for the treatment of ER+ cancers including breast cancer are described.